VASOACTIVE NATRIURETIC PEPTIDES AND KIDNEY

Ljiljana Surić-Lambić¹, S. Plješa², V. Stojanov², D. Avramović²

¹ Department of Nephrology, University Teaching Hospital Zemun, Belgrade
² Institute of Cardiovascular diseases, Clinical Centre of Serbia, Belgrade, Yugoslavia

Summary. The natriuretic peptide family (ANP, BNP, CNP) is responsible for the body fluid homeostasis and blood pressure control. ANP and BNP act on guanylate cyclase-A and CNP on guanylate cyclase-B receptors. The main renal actions of ANP are: 1. direct and indirect effects on the kidney to alter renal hemodynamics, and to increase fluid and electrolyte excretion; 2. functional antagonism of the renin-angiotensin-aldosterone system (R-A-A) by inhibiting synthesis and/or release of renin and aldosterone, and by antagonising all known effects of angiotensin. ANP increases single nephron GFR in proportion of total GFR due mainly to an increase in glomerular capillary hydrostatic pressure that results from efferent arteriolar constriction and afferent arteriolar dilation. ANP indirectly acts on tubular sites that are targets of R-A-A system, including proximal tubular sites (angiotensin) and distal nephron sites (aldosterone). Regulation of CNP secretion is different from that of ANP and BNP, which are cardiac hormones. The increase of the plasma CNP in chronic renal failure (CNF) can be due to the diminished clearance of CNP in the kidney or due to increase in CNP production that occurs in the renal parenchymal cells. In chronic renal failure (CRF) exists a downregulation of ANP clearance receptors due to exaggerated ANP-stimulated cGMP response in CRF glomeruli. In hemodialysis patients, changes in plasma ANP are greater than in BNP and more responsive to changes in left atrial volume due to ultrafiltration.

Key words: Natriuretic peptides, renal disease, haemodialysis

Introduction

Many investigations have been made to explain the regulation of diuretic-natriuretic function of the kidney. Efforts were focused on the detection of diuretic and natriuretic substances (1,2). A step forward in the research on renal regulation by the heart was made when the first factor from heart atria involved in diuresis was characterized as a peptide (3). In 1981 de Bold et al (1) published the decisive experiment demonstrating that administration of crude acid extract of rat atria to anesthetized rats led to a powerful natriuretic response, sodium excretions increasing more than threefold above baseline levels, whereas a similarly prepared ventricular extract was without effect (3).

Peptides family. – The detection amino acid sequence of this cardiac peptide from rat and porcine atria revealed the atrial natriuretic-diuretic and the vasorelaxant peptide (4,5) – in the current literature under the names atrial natriuretic factor (ANF) or atrial natriuretic peptide (ANP). Subsequent studies resulted in the finding of new substances, and a family of peptides, now designated as the A-type (ANF 28), B-type (BNP 32), C-type (CNP 22) and urodilatin (ANF 32) (3), has been established. Amino acid sequence of ANF 28 and other members of the natriuretic family is shown in Fig. 1 (3).

Atrial natriuretic factor (ANF 28)

Atrial natriuretic factor, a polypeptide hormone of 28 amino acid (ANF 28) with potent vasodilator, hypotensive (7) and diuretic activities, has been purified from animal and human atrial extracts (8). Several stimuli for the release of this hormone have been identified, including volume expansion associated with increased atrial stretch and pressures (4) as well as atrial and ventricular tachyarrhythmias (3,9,10). Stretch-induced release is independent of Ca²⁺, and that removal of Ca²⁺ from the superfusate increases the rate of ANF 28 release (11).

Molecular biology of ANF 28 and ANF 32– The A-types of natriuretic peptides (ANF 28 and ANF 32) are produced by one single gene containing three exons and two intrones (12). It is localized on the short-arm position 36.1-3 of chromosome 1 in humans (6). The plasma levels of ANF 28 and the N-terminal fragment of its pro-hormone (termed N-terminal pro-ANF) correlate closely with atrial pressure. ANF 28 is rapidly
degraded by lysosomal hydrolases internalization via receptor-mediated endocytosis.

**ANF 28 receptors** – In the kidney ANF 28 acts on specific receptors. ANF 28 receptors have been identified in the glomerulus (13-16) with the majority (63%) on visceral epithelial cells, 14% on parietal cells, 13% on capillary endothelium and 10% on mesangial cells (13). All vessels of the renal arterial tree have ANF 28 receptors, including the arcuate and interlobular arteries and afferent and efferent arterioles (15), although ANF 28 receptor density appears to be greatest in the glomeruli. Glomerular ANF 28 receptor density is down-regulated when plasma ANF 28 levels are elevated, as in mineralocorticoid escape or in rats on high-salt diet (14).

**Renal actions of ANF 28** – The several nephron sites are targets for ANF 28 (3). ANF 28 increases single nephron (SN) glomerular filtration rate (GFR) in proportion of total GFR (3). The increase is mainly due to an increase in glomerular capillary hydrostatic pressure that results from efferent arteriolar constriction and afferent arteriolar dilation (3). In normal conditions, ANF 28 does not alter or even slightly decrease SN and total renal blood flow (RBF). ANF 28 is the only known endogenous substance that may increase GFR in face of a decrease in blood pressure, and an unchanged or even decreased RBF due to its generic vasorelaxant property (3).

ANF 28 markedly increases the load of sodium to the base of the inner medullary collecting duct (IMCD), an effect that is essential for a robust natriuretic response, and subsequently disrupt load-reabsorption balance in this nephron segment. The reasons for the increase in sodium load to the IMCD are multiple: increase in GFR, decrease in inner medullary hypertonicity that decreases passive fluid efflux from the thin limbs of Henle’s loop, direct tubular effects of ANP 28 that decrease sodium reabsorption in nephron segments proximal to the IMCD (17).

**ANF 28 and end stage renal disease (ESRD)**

Basal levels of ANF 28 are increased in both mild to moderate renal insufficiency and ESRD (18). A positive feedback control loop was observed in dialysis patients between ANF 28 secretion and (1) blood volume level, and (2) atrial dimensions, with ANF 28 concentration increasing with extracellular fluid volume (ECFV) expansion and decreasing after dialysis ultrafiltration (18).

Molecular forms of ANF 28 (α, β and γ) in plasma of stable haemodialysis (HD) patients differ from those of healthy volunteers. The middle-molecular-weight ANF 28 (β ANF 28) may particularly be secreted in clinically stable HD patients (19).

Plasma levels of ANF 28 and BNP 32 were measured, along with left and right atrial and left ventricular volumes, in patients with chronic renal
failure before and after the removal of fluid by ultrafiltration (UF) and again during volume repletion with i.v. NaCl sol. (20). Baseline levels of ANF 28 (46.0 ± 7.5 pmol/L) and BNP 32 (22.0 ± 4.4 pmol/L) were elevated above normal. There was a significant reduction in plasma ANF 28 (26.5 ± 4.7 pmol/L) and BNP 32 (19.1 ± 4.9 pmol/L, p < 0.05) following UF. Changes in plasma ANF 28 during UF correlated significantly with changes in left atrial volume (r = 0.643, p < 0.05). During volume repletion there was a exaggerated release of ANF 28 (mean level post repletion 71.3 ± 20.8 pmol/L), which was not paralleled by changes in BNP 32. Changes in BNP 32 were small, showing no correlation with atrial or ventricular volumes during UF or volume repletion. Changes in plasma ANF 28 are greater than BNP 32 and more responsive to changes in left atrial volume (20). However, there not yet a consensus as to the significance of a role of BNP compared with results in the Ishizaka et al. study (26).

Hypertensive haemodialysis (HD) patients. – It has been observed that while most hypertensive HD patients normalize their blood pressure (BP) with fluid removal, there is a population of HD patients whose hypertension is refractory to such treatment. The hypothesis is that: 1) ANF 28 levels are higher in hypertensive than normotensive HD patients. 2) Hypertensive HD patients who normalize their BP with HD, also normalize their ANF 28 levels. 3) Hypertensive HD patients whose BP is refractory to fluid removal do not normalize their ANF 28 levels with volume removal, supporting the hypothesis that these patients remain significantly fluid overloaded after HD (21).

Renal transplation. – In subjects undergoing renal transplantation, despite an adequate density of glomerular ANF 28 receptors and enhanced cGMP generation, neither renal vasoconstriction nor hypofiltration is alleviated by a progressive elevation of plasma ANF 28 levels in renal transplant recipients with sustained posts ischemic injury. That means that constricted afferent arterioles are unresponsive to the vasorelaxant action of endogenous ANF 28 in this form of posts ischemic, acute renal failure (22).

Brain natriuretic peptide (BNP 32)

BNP 32 was first isolated from the porcine brain, and it has a striking similarity to ANF 28 with regard to both its amino acid sequence and pharmacological spectrum (23). BNP 32 is also synthesized in and secreted from the porcine heart (24). Unlike ANF 28, BNP 32 shows species variation in both its structure and tissue distribution.

Plasma BNP 32 before and after hemodialysis. – In patients before HD, a 14 to 2.300-fold increase in plasma level of immunoreactive (ir-) BNP 22 was observed when compared to normal controls. A ratio of BNP 32 to pro-BNP in plasma from the patients was much larger than that in plasma from normal subjects, indicating that the high plasma level of ir-BNP level in the patients on HD largely results from a marked increase in BNP 32. Hemodyalisis significantly (p < 0.01) lowered the plasma levels of both BNP 32 and pro-BNP, with a greater reduction in BNP 32 than in pro-BNP. Whereas, ANF 28 was a main molecular form of plasma ANF in both pre- and post-HD plasma.

These suggest that plasma BNP 32 plays an important role in the sodium-fluid balance and that secretion and metabolism of BNP 32 may differ from those of ANF 28 in the HD patients (25).

In the other study, BNP 32 was measured in 40 patients on HD and in 12 healthy subjects. The mean (±SD) plasma BNP 32 level in the patients before HD (18.4 ± 3.4 fmol/mL) was markedly higher than that in the control group (0.39 ± 0.08 fmol/mL). The plasma BNP 32 level was significantly decreased by HD from 18.4 ± 3.4 fmol/mL to 10.5 ± 2.2 fmol/mL, p < 0.001), but the latter value was still higher than the upper limit of the normal range (26). The correlation was not observed between the plasma BNP 32 level and mean blood pressure. Ultrasound studies in 13 patients revealed correlations between the ANF 28 level before HD and the interventricular septal thickness index (r = 0.68, p < 0.05) and between the change in BNP 32 levels and left atrial diameter (r = 0.806, p < 0.001). In conclusion, BNP 32 and ANF 28 levels correlated with several parameters of volume change and cardiac status (26), which is in contrast to results in Corboy et al. study (20).

C-type natriuretic peptide (CNP 22)

The third member of the natriuretic peptide family, CNP 22, has recently been isolated from the porcine brain and is reported to act principally as a neuropeptide (27) and is also produced in cultured vascular endothelial cells (28,29). CNP 22 is known to act via two types of receptors, natriuretic peptide receptors B and C (30). The former of these is linked to guanylate cyclase, causing accumulation of cGMP; the latter produces several effects including inhibition of cAMP synthesis (31). Suga et al. (32) reported the in vivo gene expression of CNP 22 and its specific receptor, guanylate-cyclase-B (GC-B) receptor, in intact vessels. CNP 22 can induce relaxation and growth-inhibition of vascular smooth muscle cells as a novel endothelium-derived relaxing peptide (33).

The differences of the potency of CNP 22, ANF 28 and BNP 32 can be partly attributed to the differences in the distribution of GC-A receptors, which show a high affinity to ANF 28 and BNP 32, and GC-B receptors which are specific to CNP 22 (32). GC-A is widely distributed in humans and predominantly exists in the lung, kidney and blood vessels, which are the target
organs of intravenous-administered natriuretic peptides, whereas GC-B expression in those organs is less abundant (32).

In contrast with ANF 28 and BNP 32, CNP 22 appears to be secreted predominantly from the vascular endothelium (28). The diuretic and natriuretic effects of CNP 22 are limited in comparison with ANF 28 and BNP 32 (34).

CNP 22 is involved in the local regulation of the vascular renin-angiotensin system. It inhibits the vasoconstrictor effect of angiotensin I more than it inhibits the vasoconstrictor effect of angiotensin II. This suggests an important role for CNP 22 as a paracrine regulator of vascular ACE activity (35). ACE activity in cultured endothelial cells is stimulated by cAMP and by agents that increase its production but is not affected by cGMP, suggesting that CNP 22 may act via natriuretic peptide receptor C to reduce cAMP production and inhibit ACE activity (35).

CNP 22 and hemodialysis therapy. – To investigate the significance of CNP 22 as an endothelin-relaxing peptide in renal functions in humans, the plasma CNP 22 level in chronic renal failure (CRF) patients (n = 7), who were under hemodialysis therapy, was examined (36). The significant increase of the plasma CNP 22 level (3.0 ± 0.4 fmol/ml) in patients with CRF vs healthy humans (1.4 ± 0.6 fmol/ml) can be partly due to the diminished clearance of CNP 22 (36). However, another possibility remains; an increase in CNP 22 production may occur in the renal parenchymal cells, leading to elevated plasma CNP 22 (37).

In the other study, plasma CNP 22 levels were greatly elevated in patients with CRF [non-dialysed, 13.0 ± 4.2 fmol/L, n = 9, p < 0.01 compared with normal subjects (4.4 ± 0.4 pmol/L, n = 26); hemodialysis 16.1 ± 2.1 pmol/L, n = 13, p < 0.01], but non in patients with congestive heart failure (CHF, NYHA class II-IV) (3.0 ± 0.7 pmol/L, n = 11, p > 0.05). Plasma ANF 28 and BNP 32 levels were elevated both in patients with CHF and in HD patients with CRF. These findings suggest that CNP 22 is a non-cardiac circulating hormone and participates in the cardiovascular regulation in a different manner from ANF 28 and BNP 32 (38).

Renal natriuretic peptide - urodilatin (ANF 32)

The different natriuretic peptides (NPs) were recognized to be mainly important as cardiovascular regulatory hormones. Several observations led to the conclusion that in extracardiac NP systems, namely that of the kidney, may exist NP-immunoreactive substances that were demonstrated by immunohistochemistry in tubular epithelial cells of the kidney. Actually, it is known that A-type (39) and C-type (40) natriuretic peptides are localized in kidney cells of the distal tubules. These peptides can be measured by radioimmunoassay in kidney tissue. Isolation and amino acid sequence analysis of the urinary form of the A-type NP resulted in the discovery of A-new factor – ANF 32 (urodilatin) (6, 41).

In contrast to the circulating form of A-type NP with its 28 amino acid containing chain (ANF 28), urodilatin represent a peptide of 32 amino acids (ANF 32) lengthened at the N-terminus of the circulating form by Thr-Ala-Pro-Arg. It is postulated that the peptides are derived from the common gene in chromosome 1. (Fig. 1) (6).

The mechanism how the exact synthesis of ANF 32 happens is still unclear. Two hypothesis (6) may be proposed: (1) ANF 32 is processed from minor quantities of circulating cardiogenic precursor which is sufficient when cleared from the circulation and cleaved in the kidney, and (2) the produced ANF 32 is really synthesized in distal tubular cells and cleaved there from the precursor (6,42,43). ANF 32 is a typical paracrine factor regulating intrarenal functions (5) and resistant to degradation by the endoprotease (EC 24.11) (6).

Physiology. – Receptors of the collecting ducts may be the target under physiological conditions. The natriuretic peptide luminal receptors B (NPR-B) are physiologically the only targets for ANF 32. Recently, it has been shown by polymerase chain reaction that urodilatin-sensitive receptors are expressed in the human kidney (44). ANF 32 binds to renal receptors (45) and activates the targets via cyclic guanosine monophosphate (cGMP) increase. Its tubular effect is a result of its interaction with the amiloride-sensitive sodium channels.

ANF 32 peptide closely relates to diurnal rhythm of natriuresis and intermittent water-sodium load, dietary sodium changes and renal sodium excretion (46), and reduction of natriuresis during microgravity (47). The regulation of ANF 32 peptide secretion is unclear, but may be triggered by a humoral factor induced among other things by brain salt load reaching the kidney by means of a humoral pathway (6).

Clinical application

Acute renal failure. – It has been shown in animal experiments that natriuretic peptides may prevent or attenuate ischemic renal failure. In animal experiments, ANF 32 peptide in contrast to sodium nitroprusside improves the state of acute renal failure (48).

Cardiac transplantation. – Some investigators observed significant benefits using a 4-day infusion of ANF 32 peptide after heart (49, 50) or liver and heart transplantations (51).

Bone marrow transplantation. – Acute renal failure was imminent in an 18-month-old male infant 20 days after unrelated bone marrow transplantation (BMT). The infant was treated with urodilatin and furosemide infusions. After seven days of urodilatin (ANF 32) treatment diuresis was normal, the serum
creatinine level had decreased, and furosemide was reduced. No side effects were observed (52).

**Liver transplantation** – Eight patients who developed acute renal failure (ARF) after liver transplantation and fulfilled requirements for hemodialysis / hemo-filtration were treated. After low dose ANF 32 (urodilatin) infusion was started, renal function improved and all patients developed a strong diuresis and natriuresis within 2-4 h. The study shows that continuous low dose ANF 32 infusion may present a new concept for treatment of postoperative acute renal failure resistant to conventional therapy (53).

**References**


Vasoactive Natriuretic Peptides and Kidney

Ljiljana Surić-Lambić1, S. Plješa1 V. Stojanov2, D. Avramović1

1 KBC Zemun, Nefrološko odeljenje Internističke službe, Beograd
2 Institut za kardiovaskularne bolesti Kliničkog centra Srbije, Beograd, Jugoslavija

Kratak sadržaj: Porodica natriuretskih peptida odgovorna je za homeostazu telesne tečnosti i kontrolu krvnog pritiska. ANP i BNP deluju preko gvanilat-ciklaza A a CNP preko gvanilat-ciklaza B receptora. Glavna dejstva ANP su: 1. neposredni i posredni uticaj na hemodinamske promene u bubregu, čime je povećano izlučivanje tečnosti i elektrolita; 2. suprotstavljanje funkciji renin-angiotenzin-aldosteron (RAA) sistema putem inhibicije stvaranja i/ili oslobađanja renina i aldosterona, i neutralisanjem svih poznatih efekata angiotenzina. ANP povećava glomerulsku filtraciju (GF) u svakom pojedinačnom nefronu zavisno od ukupne GF uglavnom na račun povećanja hidrostatskog pritiska i glomerulara regulisanim konstrikcijom eferentne i dilatacijom aferentne arteriole. ANP posredno deluje na mestima uticaja RAA sistema u tubulima uključujući proksimalni (angiotenzin) i distalni (aldosteron) tubul.

Ključne reči: Natriuretski peptidi, bubrežne bolesti, hemodializa

Received: September 18, 1997